GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
CVS Corporation (CVS) [hlAlert]

Rating:
Buy CVS
up 29.70 %

CVS Corporation (CVS) rated Buy by Standpoint Research

Posted on: Monday,  Dec 8, 2008  8:25 AM ET by Standpoint Research

Standpoint Research rated Buy CVS Corporation (NYSE: CVS) on 12/08/2008, when the stock price was $27.91. Since then, CVS Corporation
has gained 29.70% of its value until Standpoint Research rated CVS Hold on 04/28/2011, when the price was $36.20.
If you would have followed this Standpoint Research's recommendation on CVS, you would have gained 29.7% of your investment in 871 days.

CVS Caremark Corporation (CVS Caremark) is a provider of prescriptions and related healthcare services in the United States. It is a pharmacy services company and drives value for its customers through its approximately 6,900 CVS/pharmacy and Longs Drug retail stores; CVS Caremark?s pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services; its retail-based health clinic subsidiary, MinuteClinic, and Its online pharmacy, CVS.com. The Company operates in two business segments: Pharmacy Services and Retail Pharmacy. October 20, 2008, CVS Caremark acquired Longs Drug Stores Corporation, which includes 529 retail drug stores (the Longs Drug Stores) and RxAmerica LLC (RxAmerica), which provides pharmacy benefit management services, and certain other related assets.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/19/2014 12:00 AM Sell
None
76.27 62.00
as of 12/24/2008
1 Week down  -1.36 %
1 Month up  6.52 %
3 Months   
1 YTD up  6.52 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/28/2011 10:25 AM Hold
None
36.20
12/8/2008 8:25 AM Buy
None
27.91

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy